Authors: Delmas, PD Pornel, B Felsenberg, D Stakkestad, JA Radowicki, S Garnero, P Hardy, P Dain, MP Petitier, B

Citation: Pd. Delmas et al., Three-year follow-up of the use of transdermal 17 beta-estradiol matrix patches for the prevention of bone loss in early postmenopausal women, AM J OBST G, 184(2), 2001, pp. 32-40

Authors: Delmas, PD Hardy, P Garnero, P Dain, MP

Citation: Pd. Delmas et al., Monitoring individual response to hormone replacement therapy with bone markers, BONE, 26(6), 2000, pp. 553-560

Authors: Notelovitz, M Cassel, D Hille, D Furst, KW Dain, MP VandePol, C Skarinsky, D

Citation: M. Notelovitz et al., Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause, AM J OBST G, 182(1), 2000, pp. 7-12

Authors: Delmas, PD Pornel, B Felsenberg, D Garnero, P Hardy, P Pilate, C Dain, MP

Citation: Pd. Delmas et al., A dose-ranging trial of a matrix transdermal 17 beta-estradiol for the prevention of bone loss in early postmenopausal women, BONE, 24(5), 1999, pp. 517-523

Authors: Cooper, C Stakkestad, JA Radowicki, S Hardy, P Pilate, C Dain, MP Delmas, PD

Citation: C. Cooper et al., Matrix delivery transdermal 17 beta-estradiol for the prevention of bone loss in postmenopausal women, OSTEOPOR IN, 9(4), 1999, pp. 358-366

Authors: Archer, DF Furst, K Tipping, D Dain, MP Vandepol, C

Citation: Df. Archer et al., A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause, OBSTET GYN, 94(4), 1999, pp. 498-503